Okyo Pharma Share Discussion Threads

[newtothisgame3] 17/4/2019 04:09

#OKYO #Pharma #Ltd
#OKYO : #LSE Momentum
2019 Apr 16 DAILY
Short-Term #Bullish

[newtothisgame3] 17/4/2019 04:09

#OKYO #Pharma #Ltd
#OKYO : #LSE Momentum
2019 Apr 16 DAILY
Short-Term #Bullish

[newtothisgame3] 17/4/2019 04:09

#OKYO #Pharma #Ltd
#OKYO : #LSE Momentum
2019 Apr 16 DAILY
Short-Term #Bullish

[discodave4] 16/4/2019 22:22

Sorry wrong board

[newtothisgame3] 16/4/2019 20:42

#OKYO #STRONG #BUY LOOK

[newtothisgame3] 16/4/2019 20:42

#OKYO #STRONG #BUY LOOK

[newtothisgame3] 16/4/2019 20:41

#OKYO #STRONG #BUY LOOK

[newtothisgame3] 16/4/2019 20:37

#OKYO closed up 28.0 percent on Tuesday, April 16, 2019, on 14.42 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

[newtothisgame3] 16/4/2019 20:36

#OKYO closed up 28.0 percent on Tuesday, April 16, 2019, on 14.42 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

[newtothisgame3] 16/4/2019 20:36

#OKYO closed up 28.0 percent on Tuesday, April 16, 2019, on 14.42 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

[bibs] 16/4/2019 16:00

Those in the know ..... ?

[soultrading] 16/4/2019 14:21

Partnership ???

[newtothisgame3] 10/4/2019 21:42

!FOLLOWFEED!YOUTUBEVIDEO:nfumP5CKe7c:
OKYO Pharma Ltd on Thursday said it will present preclinical results demonstrating anti-inflammatory activity and the potential of OKYO-0101 in the treatment of dry eye.



The biotechnology firm said treatment with OKYO-0101 reduced "significantly" the increase in corneal permeability due to dry eye. Furthermore, the product normalised the dry eye induced loss of goblet cell density.

Rabbit ocular tolerance test using OKYO-0101 showed "no adverse signs" such as inflammation, chemosis or hyperemia and signs of local irritation, the company added.

By Elena Cherubini; [e-mail]

Inflammation and oncology are the expertise of Okyo Pharma's board


OKYO Pharma sees big opportunities for its dry eye and pain management technology

Kunwar Shailubhai, chief executive of OKYO Pharma Plc (LON:OKYO) discusses with Proactive's Andrew Scott the new direction and investment strategy for the business following its name change earlier this year.

He says they've found two 'exciting' new technologies focused on dry eye and pain management.

'Both are worldwide epidemics ... we think there's a lot of opportunity'', he says.

[newtothisgame3] 06/4/2019 21:37

#OKYO ULEZ charge: How will London's ultra-low emission zone affect Londoners?
Future London spoke to groups of experts, residents and businesses to find out
what it means for them

[newtothisgame3] 06/4/2019 21:36

#OKYO ULEZ charge: How will London's ultra-low emission zone affect Londoners?
Future London spoke to groups of experts, residents and businesses to find out
what it means for them

[newtothisgame3] 29/3/2019 21:13

#OKYO 4 STAR BUY

[newtothisgame3] 29/3/2019 21:03

#OKYO #PHARMA Pocket Pivot #Bullish Swing Setup

[newtothisgame3] 29/3/2019 21:00

#OKYO #BUY 🔥👀

[newtothisgame3] 29/3/2019 14:40

OKYO on the move

[newtothisgame3] 29/3/2019 08:27

#OKYO keep your 👀on it SOMETHING AFOOT NO TRADES YET